Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

Sanofi and Regeneron’s dupilumab has been given a priority review by the FDA, putting the first-in-class drug on course for a likely approval by 29 March. The drug is for adult patients with ...

In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type-2 inflammation or other allergic processes in phase 3 ...

1 Dupilumab is being jointly developed by Regeneron and Sanofi ... in this press release, on any of the foregoing; the likelihood, timing, and scope of possible regulatory approval and commercial ...

Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results ... has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the ...

and Sanofi today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent ® (dupilumab) for the treatment of ...

Following recent approvals in the EU, China, and the US, this approval was based on pivotal ... and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive ...

Dupilumab development program Dupilumab is being jointly developed by Sanofi ... this press release, on any of the foregoing; the likelihood, timing, and scope of possible regulatory approval ...